NASDAQ:ATRAAtara Biotherapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Atara Biotherapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $15.26 -0.24 (-1.55 %) (As of 07/9/2020 03:06 PM ET) Add Compare Share Today's Range$14.82Now: $15.26▼$15.6950-Day Range$8.94MA: $12.05▼$15.4652-Week Range$4.52Now: $15.26▼$19.36Volume16,328 shsAverage Volume1.80 million shsMarket Capitalization$899.58 millionP/E RatioN/ADividend YieldN/ABeta2.35 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, and autoimmune and viral diseases, including ATA2271 for mesothelin; ATA2321 for acute myeloid leukemia; and ATA2431 and ATA3219 for B-cell lymphomas, as well as ATA188 and ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis. In addition, it is developing ATA621 against the BK and JC viruses; ATA368 for patients with human papillomavirus and associated cancers; ATA520 to treat Wilms tumor 1; and ATA230 against cytomegalovirus and related diseases. The company has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 4.3 Analyst's Opinion Consensus RatingAtara Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 2.64, and is based on 8 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.75, Atara Biotherapeutics has a potential upside of 57.6% from its current price of $15.07.Amount of Analyst CoverageAtara Biotherapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.8 Community Rank Outperform VotesAtara Biotherapeutics has received 396 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAtara Biotherapeutics has received 315 “underperform” votes. (Add your “underperform” vote.)Community SentimentAtara Biotherapeutics has received 55.70% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Atara Biotherapeutics and other stocks. Vote “Outperform” if you believe ATRA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ATRA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAtara Biotherapeutics does not currently pay a dividend.Dividend GrowthAtara Biotherapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atara Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $156,784.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Atara Biotherapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Atara Biotherapeutics are expected to grow in the coming year, from ($4.63) to ($4.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atara Biotherapeutics is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atara Biotherapeutics is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtara Biotherapeutics has a P/B Ratio of 2.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.55 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ATRA Previous Symbol CUSIPN/A CIK1604464 Webwww.atarabio.com Phone650-278-8930Debt Debt-to-Equity Ratio0.05 Current Ratio7.27 Quick Ratio7.27Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.37 per share Price / Book2.84Profitability EPS (Most Recent Fiscal Year)($5.67) Net Income$-290,980,000.00 Net MarginsN/A Return on Equity-109.01% Return on Assets-93.10%Miscellaneous Employees321 Outstanding Shares58,950,000Market Cap$899.58 million Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:ATRA Rates by TradingView Receive ATRA News and Ratings via Email Sign-up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Atara Biotherapeutics (NASDAQ:ATRA) Frequently Asked Questions How has Atara Biotherapeutics' stock been impacted by COVID-19 (Coronavirus)? Atara Biotherapeutics' stock was trading at $9.96 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ATRA stock has increased by 51.3% and is now trading at $15.07. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Atara Biotherapeutics? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last year. There are currently 1 sell rating, 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Atara Biotherapeutics. When is Atara Biotherapeutics' next earnings date? Atara Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Atara Biotherapeutics. How were Atara Biotherapeutics' earnings last quarter? Atara Biotherapeutics Inc (NASDAQ:ATRA) announced its quarterly earnings data on Wednesday, May, 6th. The biotechnology company reported ($1.20) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.41) by $0.21. View Atara Biotherapeutics' earnings history. What price target have analysts set for ATRA? 11 brokerages have issued 12-month price targets for Atara Biotherapeutics' stock. Their forecasts range from $9.00 to $38.00. On average, they anticipate Atara Biotherapeutics' stock price to reach $23.75 in the next twelve months. This suggests a possible upside of 57.6% from the stock's current price. View analysts' price targets for Atara Biotherapeutics. Has Atara Biotherapeutics been receiving favorable news coverage? Headlines about ATRA stock have been trending negative on Thursday, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Atara Biotherapeutics earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about Atara Biotherapeutics. Who are some of Atara Biotherapeutics' key competitors? Some companies that are related to Atara Biotherapeutics include bluebird bio (BLUE), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Immunovant (IMVT), Twist Bioscience (TWST), Alector (ALEC), Editas Medicine (EDIT), Adverum Biotechnologies (ADVM), SpringWorks Therapeutics (SWTX), Sorrento Therapeutics (SRNE), Bill.com (RVMD), Sangamo Therapeutics (SGMO), Mesoblast (MESO), Beam Therapeutics (BEAM) and Regenxbio (RGNX). View all competitors. What other stocks do shareholders of Atara Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include Crispr Therapeutics (CRSP), AbbVie (ABBV), Gilead Sciences (GILD), Micron Technology (MU), Amarin (AMRN), Editas Medicine (EDIT), Exelixis (EXEL), Karyopharm Therapeutics (KPTI), Advanced Micro Devices (AMD) and ImmunoGen (IMGN). Who are Atara Biotherapeutics' key executives? Atara Biotherapeutics' management team includes the following people: Dr. Isaac E. Ciechanover, Pres, CEO & Director (Age 48)Mr. Utpal Koppikar, Chief Financial Officer (Age 49)Mr. Joseph Newell, Exec. VP & Chief Technical Operations Officer (Age 49)Ms. Mina Kim, Sr. VP of Corp. Strategy, Gen. Counsel & Sec. (Age 45)Dr. Dietmar P. Berger M.D., Ph.D., Global Head of R&D (Age 56) What is Atara Biotherapeutics' stock symbol? Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA." How do I buy shares of Atara Biotherapeutics? Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Atara Biotherapeutics' stock price today? One share of ATRA stock can currently be purchased for approximately $15.07. How big of a company is Atara Biotherapeutics? Atara Biotherapeutics has a market capitalization of $888.38 million. The biotechnology company earns $-290,980,000.00 in net income (profit) each year or ($5.67) on an earnings per share basis. Atara Biotherapeutics employs 321 workers across the globe. What is Atara Biotherapeutics' official website? The official website for Atara Biotherapeutics is www.atarabio.com. How can I contact Atara Biotherapeutics? Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-278-8930. This page was last updated on 7/9/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
